Annals of Pharmacotherapy · 2011 · 77 citations · 20 references
MedicineHematologyPharmacotherapyHemostasisTransfusion MedicineTrauma Critical CareAnticoagulant ManagementAnticoagulation ManagementAnticoagulation TherapyThromboembolism PreventionThrombosisVitamin K TherapyFresh Frozen Plasma TherapyIntensive Care Unit MortalityInternational Normalized Ratio ReversalMedical Records ReviewProthrombin Complex Concentrate UseThromboprophylaxis In Trauma PatientsTrauma Registry DesignWarfarin Reversal
BACKGROUND: Prothrombin complex concentrate (PCC) is recommended as a therapy to be considered for the reversal of warfarin's effects. Few published data are available on the use of PCC for this indication in traumatically injured patients. OBJECTIVE: To determine whether the addition of PCC to standard approaches to warfarin reversal more rapidly corrects the international normalized ratio (INR) in injured patients. METHODS: A retrospective analysis was performed in trauma patients who were on warfarin preinjury from January 2007 to September 2009 at North Memorial Medical Center. Data were collected from medical records and the trauma registry. Patients were separated based on whether or not they received PCC. The groups were compared on the basis of demographics, units of fresh frozen plasma (FFP), vitamin K use, units of PCC, number of patients achieving an INR of 1.5 or less, time to an INR of 1.5 or less, mortality, intensive care unit (ICU) and hospital length of stay, and the incidence of thromboembolic events during hospitalization. RESULTS: Thirty-one patients were included in the analysis; 13 patients who received a total mean (SD) dose of 2281 (1053) units (25.6 [12.2] units/kg) of PCC (Profilnine SD) were compared to 18 patients who did not receive PCC. There was no significant difference between groups in FFP units received or the number of patients who received vitamin K. Most patients in both groups achieved an INR of 1.5 or less (92% PCC vs 89% no PCC). However, the mean time to achieve an INR of 1.5 or less was 16:59 (20:53) hours in the PCC group versus 30:03 (23:10) hours in the no PCC group (p = 0.048). There were 3 deaths in the PCC group and no deaths in the no PCC group (p = 0.06). ICU and hospital length of stay and number of thromboembolic events did not differ significantly between the 2 groups. CONCLUSIONS: PCC, when added to FFP and vitamin K, resulted in a more rapid time to reversal of the INR.
20
Pharmacology and Management of the Vitamin K Antagonists
Jack Ansell, Jack Hirsh, Elaine M. Hylek et al. · CHEST Journal · 2008 · 2.1K citations
The Pharmacology and Management of the Vitamin K Antagonists
Jack Ansell, Jack Hirsh, L. Poller et al. · CHEST Journal · 2004 · 1.5K citations
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Sam Schulman, Rebecca J. Beyth, Clive Kearon et al. · CHEST Journal · 2008 · 732 citations
Ingrid Pabinger, Benjamin Brenner, Uwe Kalina et al. · Journal of Thrombosis and Haemostasis · 2008 · 312 citations · Full text